GlobeNewsWire
30 Jun 2026, 20:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ARS Pharmaceuticals' neffy (epinephrine nasal spray) failed to secure commercial insurance coverage. — Lack of insurance coverage severely limits market penetration and revenue potential for a primary drug product.
-0.80Pomerantz LLP is investigating ARS Pharmaceuticals for potential securities fraud or unlawful business practices. — The prospect of a class action lawsuit introduces legal risk and potential financial liabilities for the company.
-0.50ARS Pharmaceuticals' stock price dropped 23.91% following the news of payer access failures. — Confirms immediate negative market sentiment and loss of investor confidence in the company's valuation.
-0.30Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is facing a class action investigation following a significant stock price drop and failure to secure insurance coverage for its product.
The company is the subject of an investigation by a law firm on behalf of investors.
The company is the subject of an investigation by a law firm on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
44m ago
